European Medicines Association (EMA) statement on Obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis (PBC)
The European Medicines Association (EMA) issued a statement on Obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis (PBC) on 28 06 2024.
The EMA has recommended that the marketing authorisation for Ocaliva be revoked in the European Union following results of the COBALT trial, 747-302 . In the UK EMA recommendations do not apply, as we are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). At present, there are no changes to the recommendations on use of Obeticholic acid in PBC from the MHRA or the National Institute for Health and Care Excellence (NICE) and so current prescribing practices should NOT change.
We shall update the UK liver community if there are any changes to the recommendations on the use of Obeticholic acid.
The National Primary Care Diagnostic Pathway for lower gastrointestinal (GI) symptoms is now live
We are delighted that the National Primary Care Diagnostic Pathway for lower gastrointestinal (GI) symptoms is now live on the dedicated website.
Congratulations and welcome to our newest BSG Officers!
Congratulations to our new BSG Officers coming into post from June 2024.
2024 BSG Elections Results
We are delighted to share the results of the 2024 BSG Summer Elections.